|Bid||0.5400 x 1000|
|Ask||1.0800 x 1000|
|Day's Range||0.7200 - 0.7899|
|52 Week Range||0.5000 - 1.1500|
|PE Ratio (TTM)||-1.97|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||2.30|
AVEO Oncology today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , as part of the Marketing Authorization Application review process for tivozanib as a treatment for patients with first-line renal cell carcinoma .
AVEO Oncology today announced the appointment of Matthew Dallas as chief financial officer, effective June 1, 2017. In this role, Mr. Dallas will be responsible for the Company’s financial strategy and management as it takes steps toward the potential commercialization of tivozanib.
The Board of Directors of AVEO Oncology today issued the following statement regarding the passing of its Lead Director Henri A. Termeer.